HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT03697252

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

Medication studyAges 18–60United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Listed locations
Little Rock and 11 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study clarity

Study information

Study start dateStarted: September 18, 2018
Recruitment status
Completed
Enrollment listed in the registry
182
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 60 Years
Official registry ID
NCT03697252
Official title
Show the full official title

A Phase 2, Randomized, Double-blinded Study to Assess the Safety, Tolerability, and Efficacy of KarXT in Hospitalized Adults With DSM-5 Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Little Rock · Lemon Grove · Long Beach

9 more locations
  • Orange
  • San Diego
  • Atlanta
  • Gaithersburg
  • Berlin
  • Dayton
  • Austin
  • DeSoto
  • Richardson
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

Did this study involve medication?

Yes. The study involved medication, including Xanomeline and Trospium Chloride Capsules and Placebo Capsules.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies